For the past few years, a coterie of biotech executives, desperate patients and ideologues have waged a low-level but steady campaign to convince the country that the Food and Drug Administration is condemning sick Americans to death by denying them potentially life-saving cancer drugs and other treatments. For all three,...
Serious doubts surround the expensive anti-anemia drugs widely prescribed for the fatigue associated with cancer chemotherapy and kidney dialysis. They are also given to decrease the need for blood transfusions. But the latest studies show that these injectable drugs, sold under the brand names of Aranesp, Procrit...
The FDA has approved the use of Avastin bevacizumab in combination with carboplatin and paclitaxel for the initial systemic treatment of patients with unresectable, locally advanced, recurrent or metastatic, non-squamous, non-small cell lung cancer. This approval was based on an improvement in survival time when Avastin...
WASHINGTON -- A new treatment that slows the spread of advanced kidney cancer won government approval Tuesday, offering potential relief from a disease that kills 12,000 Americans a year. It's the first new treatment option for kidney cancer patients in more than a decade. ...
M2 PRESSWIRE-22 April 2005-US FDA: FDA names Dr. Richard Pazdur to lead new cancer officeC1994-2005 M2 COMMUNICATIONS LTD RDATE:22042005 The Food and Drug Administration FDA today announced that Richard Pazdur, M.D., F.A.C.P. will lead its newly established Office of Oncology Drug...
Taxotere, a drug derived from the needles of the European yew tree, has shown promise in fighting cancer. Richard Pazdur of the University of Texas M.D. Anderson Cancer Center in Houston and his colleagues studied the safety of taxotere by giving varying amounts of the drug to 39...
Articles 1993-01-09
<< Previous
page 1 of 1
Next >>
Premier Vendor Content
Whitepapers, webcasts & resources from our Power Center Sponsors